Kibow Biotech nominated for Buzz of BIO

Kibow Biotech nominated for Buzz of BIO

This is the first time that a biotechnology business specializing exclusively in dietary supplements has been nominated for the "Pipeline of Promise or Technologies of Tomorrow" category.

Kibow Biotech is pleased to participate in the Buzz of BIO for the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23 to 26, 2014 at the San Diego Convention Center in California. During the Buzz of BIO contest, industry leaders as well as the general public will be voting for companies they want to see at the event's BIO Business Forum. Voting will take place online from April 15 through April 22 at 

This is the first time that a biotechnology business company exclusively specializing on dietary supplement products is being recognized as one of the selected and nominated among 40 U.S. companies for the "Pipeline of Promise or Technologies of Tomorrow" category. Dr. Natarajan Ranganathan, the cofounder and chief R&D scientist, said that "the decade of research efforts on the concept of balancing the gut microbiome with probiotics (beneficial health impacting microbes) is finally gaining more recognition.” He also added that a scientific basis and rationale for "a shift from human genome to gut microbiome" has been established only recently, and the process of using it to address various health care problems is just beginning. 

Kibow's management believes that despite being a dietary supplement company, Kibow was selected because of the scientific and drug-like validation of its patented, proprietary probiotic product for maintaining healthy kidney function. Kibow is best known for its veterinary (Azodyl®) and human (Renadyl) products for individuals with compromised kidney health.  

The company's nomination is a cumulative impact of its earlier selection for a poster presentation as Emerging Biotech Company at the BIO-Boston meeting, its novel concept, and its pharmaceutical-like validation of the product based on "enteric uremic toxin reduction technology" (Enteric Dialysis®). This dietary supplement product, in combination with the standard-of-care treatment for primary diseases such as diabetes, hypertension and other related conditions, offers additional kidney support. Kibow and its R&D team have also developed a proprietary blend of prebiotics for multitargeted wellness application and is looking for partnering with a major international pharmaceutical or biotech company. 


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.